| Q56901675 | A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose |
| Q37945217 | Adenoviral producer cells |
| Q27013568 | Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines |
| Q39319692 | Bioprocess development for canine adenovirus type 2 vectors. |
| Q38013964 | Cancer immunotherapy: a paradigm shift for prostate cancer treatment |
| Q52430592 | Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats. |
| Q58563112 | Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis |
| Q37944322 | Downstream processing of cell culture-derived virus particles |
| Q38878799 | Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions |
| Q64374760 | Implementation of at-line capillary zone electrophoresis for fast and reliable determination of adenovirus concentrations in vaccine manufacturing |
| Q47553772 | In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease |
| Q37718852 | Innate immunity to adenovirus |
| Q38443390 | Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials |
| Q36318198 | Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses |
| Q37310677 | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model |
| Q26750912 | Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens |
| Q26752807 | Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses |
| Q37448942 | Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time |
| Q40684243 | Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate |
| Q33930161 | Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas |
| Q30226988 | Production of adenovirus vectors and their use as a delivery system for influenza vaccines |
| Q93162287 | Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer |
| Q36523465 | The Effect of CXCR4 Overexpression on Mesenchymal Stem Cell Transplantation in Ischemic Stroke |